Efficacy and safety of combined decitabine and ruxolitinib in the treatment of chronic myelomonocytic leukemia


Jiaming Li;Sujiang Zhang;Yubao Chen;Zeying Yan;Ying Wang;Zhiyin Liu;Haimin Sun;Yu Chen;Department of Hematology, Ruijin Hospital North affiliated to Shanghai Jiao Tong University School of Medicine;


Department of Hematology, Ruijin Hospital North affiliated to Shanghai Jiao Tong University School of Medicine;


Objective The aim of the study was to evaluate the clinical efficacy of decitabine(DEC) combined with ruxolitinib(RUX) in the treatment of chronic myelomonocytic leukemia(CMML).Methods The clinical characteristics of 12 patients with CMML were analyzed retrospectively and subsequent target sequencing was performed to investigate the efficacy of the combined treatment with DEC and RUX and the molecular signatures therein. Results Among the 12 cases, clinical improvement was observed in all patients(100%), spleen reduction was observed in six patients(67%), and hematologic improvement was observed in four patients(33%). In the CMML-1 group, the overall response was 50%(3/6), one case achieved complete response, one achieved bone marrow remission, and one achieved hematological improvement. In the CMML-2 group, the overall response was 17%(1/6), one case achieved complete response, four showed disease progression(PD), and one exhibited no response. As expected, ASXL1 mutation was predictive for the outcome of CMML(hazard ratio of 2.97, 95% confidence interval of 1.21–7.06; P = 0.02).Conclusion The use of DEC combined with RUX in the treatment of CMML effectively improved the clinical response and quality of life, especially for CMML-1 patients. Ongoing clinical trials will further evaluate the safety and efficacy of this novel therapeutic approach.


decitabine(DEC);;ruxolitinib(RUX);;chronic myelomonocytic leukemia(CMML)


To explore the background and basis of the node document

Springer Journals Database

Total: 2 articles

  • [1] Silvan Francke;;Anna Mies;;Manja Meggendorfer;;Uta Oelschlaegel;;Ekaterina Balaian;;Silke Gloaguen;;Torsten Haferlach;;Gerhard Ehninger;;Martin Bornh?user;;Uwe Platzbecker, Disease-modifying activity of ruxolitinib in a patient with JAK2 -negative CMML-2, Leukemia & Lymphoma,
  • [2] Mrinal M. Patnaik;;Ayalew Tefferi, Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management, American Journal of Hematology,

Similar documents

Documents that have the similar content to the node document

  • [1] Masahiro Iizuka;Taku Harada;Hiro-o Yamano;Takeshi Etou;Shiho Sagara;, Typical gastroduodenal endoscopic findings in a Crohn's disease patient in remission stage, World Journal of Gastrointestinal Endoscopy, 2012 (03)
  • [2] Aleksander Krag;Hans Israelsen;Bjrn von Ryberg;Klaus K Andersen;Flemming Bendtsen;, Safety and efficacy of Profermin~to induce remission in ulcerative colitis, World Journal of Gastroenterology, 2012 (15)
  • [3] Jie Han;Jian Wang;Jiaoying H. Wang;, How to achieve deep remission in treatment of inflammatory bowel disease, Journal of Traditional Chinese Medicine, 2013 (04)
  • [4] Andrea Morgner;Stephan Miehlke;Manfred Stolte;Andreas Neubauer;Birgit Alpen;Christian Thiede;Hermann Klann;Franz-Xaver Hierlmeier;Christian Ell;Gerhard Ehninger;Ekkehard Bayerdorffer;, Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pyloriassociated gastric low-grade marginal zone B-cell lymphoma of MALT type, World Journal of Gastroenterology, 2001 (02)